Form 8-K · Current report
Zoetis 8-K, filed Nov 5, 2026
- Filed
- CIK
- 0001555280
- Accession no.
- 0001555280-26-000048
Summary
Zoetis reported third-quarter 2026 revenue of $2.4 billion, down 1% from a year earlier, with net income of $591 million (down 18%) and adjusted diluted EPS of $1.75 (up 3%), and narrowed its full-year 2026 revenue guidance to $9.22–$9.32 billion while raising adjusted diluted EPS guidance to $6.25–$6.35. CEO Kristin Peck said the quarter was in line with expectations, with companion animal pressure partly offset by livestock and diagnostics growth, and the company cited FDA approval of Convenia RTU for Dogs and an FDA emergency use authorization for Simparica Trio against New World screwworm infestations in dogs.
Key points
- Third-quarter 2026 revenue was $2.4 billion, down 1% reported and organic operational; U.S. segment revenue fell 6% to $1.2 billion while International rose 4% to $1.1 billion.
- Adjusted net income was $720 million, down 5% reported and 7% organic operational, excluding $129 million in purchase accounting adjustments, acquisition and divestiture costs and certain significant items.
- Zoetis narrowed full-year 2026 revenue guidance to $9.220–$9.320 billion and raised adjusted diluted EPS guidance to $6.25–$6.35, based on foreign exchange rates as of October 20, 2026.
- In October Zoetis received FDA approval for Convenia RTU for Dogs, a long-acting antibacterial injection expected to be available to veterinarians in the first quarter of 2027, and Simparica Trio received an FDA Emergency Use Authorization for treating New World screwworm infestations in dogs and puppies.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On November 5, 2026, Zoetis Inc. (the Company) issued a press release reporting its financial results for the third quarter of 2026 and its guidance for full year 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.